✦ LIBER ✦

Long-Term Efficacy and Safety of Efavirenz Dose Reduction to 200 mg Once Daily in a Caucasian Patient with HIV

✍ Scribed by Salvador Cabrera Figueroa PhD, Alicia Iglesias Gómez, Almudena Sánchez Martín, María de la Paz Valverde Merino, Alfonso Domínguez-Gil Hurlé, Miguel Cordero Sánchez

Book ID: 118774697
Publisher: Springer International Publishing AG
Year: 2010
Tongue: English
Weight: 122 KB
Volume: 30
Category: Article
ISSN: 1179-1918
DOI: 10.1007/bf03256910

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Safety and Efficacy of Tadalaf

Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction

✍ Hartmut Porst; Jacob Rajfer; Adolfo Casabé; Robert Feldman; David Ralph; Luiz F. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Long-Term Safety and Efficacy of Tadalaf

Long-Term Safety and Efficacy of Tadalafil 5mg Dosed Once Daily in Men with Erectile Dysfunction

✍ Shindel, A. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 45 KB

Clinical efficacy and safety of telmisar

Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

✍ L. Alcocer; P. Fernandez-Bonetti; E. Campos; R. Dominguez-Henkel; J.J. DE La Fue 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

The long-term pharmacokinetics and safet

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients

✍ US Justesen; IM Hansen; ÅB Andersen; NA Klitgaard; FT Black; J Gerstoft; LR Math 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Long-Term Safety and Efficacy of a Once-

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

✍ P van Kerrebroeck; A Jardin; P van Cangh; K.U Laval 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Tu1059 A Phase 3, Randomized, Double-Bli

Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis

✍ Iwakiri, Katsuhiko; Umegaki, Eiji; Hiramatsu, Naoki; Sakurai, Yuuichi; Hori, Tet 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB